Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Riferminogene pecaplasmid
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Gene Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Riferminogene pecaplasmid is a gene therapy consisting of a recombinant DNA plasmid (NV1FGF) in a pCOR backbone, designed to express human fibroblast growth factor 1 (FGF1). Upon intramuscular injection, the plasmid is taken up by muscle cells, leading to increased local expression of FGF1 protein. This promotes angiogenesis and the formation of new blood vessels in ischemic tissues. The drug has been investigated primarily for peripheral arterial disease (PAD), including critical limb ischemia and limb amputation risk. It was developed as an angiogenic therapy aiming to improve blood flow in patients with severe vascular insufficiency[1][2][3].
- Other names
- non-viral fibroblast growth factor 1riferminogen pecaplasmidoriferminogenum pecaplasmidum
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)FGF1 (Fibroblast growth factor 1)
Beyond the preview
Go deeper on Riferminogene pecaplasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Riferminogene pecaplasmid.